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Abstract 
Purpose: Due to the rarity of vaginal intraepithelial neoplasia (VAIN), it is impossible to define the best treatment 
approach or to assess vaginal morbidity. However, brachytherapy (BT) could be a valuable choice for VAIN grade 3 
(VAIN3). The aim of this paper was to report a single-institution study of the application of high-dose-rate BT and to 
evaluate clinical outcomes as well as to investigate the dose-effect relationship for vaginal stenosis.
Material and methods: We retrospectively collected hospital records and treatment plans of 14 consecutive women 
treated in our department from August 2010 to August 2016, with HDR-BT delivered using iridium-192 by a remote 
after-loading system. Doses in 3D-planned treatment based on computed tomography (CT) were prescribed in high-risk 
clinical target volume (HR-CTV) at the vaginal wall. Vaginal stenosis was defined as vaginal shortening/narrowing 
according to CTCAE4.1. The International Commission on Radiation Units & Measurements (ICRU) bladder and rectal 
points were used for dose report analysis. The posterior-inferior border of the symphysis points was used to derive ref-
erence points. The median age of the enrolled women was 60 years, and the median total radiation dose delivered was 
35 Gy.
Results: During a median period of 15 days, the treatment was well tolerated, and no interruption was necessary. 
Acute toxicity was minimal, whereas late toxicity appeared in 4 patients as G2 and in 3 patients as G3 vaginal stenosis. 
Patients with stenosis G ≥ 2 received a higher median dose to the rectal point and were mainly over 60 years old.
Conclusions: Patients with VAIN3 seemed to benefit from BT. It is generally assumed that the vagina is radio-resis-
tant, and no constraints have yet been set, but sexual dysfunction after BT is an important cause of long-term distress. 
Finding applicable dose limits to the vagina could improve patients’ quality of life. 
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Purpose 
Vaginal intraepithelial neoplasia (VAIN) is a rare 
condition, with 0.2-0.6 cases per 100,000 women, and 
the number of cases seem to be increasing [1,2,3]. Tak-
ing into account all grades of untreated VAIN, 78% 
regress, 13% persist, and 9% progress to invasion [4]. 
With this low incidence, there is no certain treatment, 
although brachytherapy is a valid option. However, 
considering the quite long-life expectancy, long-term 
side effects due to radiation must be taken into con-
sideration. 
Although some vaginal morbidity as a result of radi-
ation to a specific part of the vagina is to be expected, the 
literature offers little data about dose-effect relationships 
in the vagina. The physical changes related to radiation 
have been well described, including adhesion of vaginal 
walls, narrowing and shortening of the vaginal barrel, 
and loss of elasticity. A concomitant decrease in vaginal 
secretions leads to dyspareunia, with a significant impact 
on quality of life [5,6,7,8,9]. 
We describe a single-institution retrospective study of 
the application of high-dose-rate (HDR) brachytherapy 
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(BT) as a radical treatment or treatment at the time of the 
first relapse of VAIN grade 3. 
Material and methods 
The records and treatment plans of 14 consecutive 
patients irradiated with HDR-BT between February 2010 
and August 2016 for high-grade VAIN (grade 3) were an-
alyzed. The following data were retrospectively collected 
for each case: patient demographics, clinical description 
of VAIN, previous treatments for VAIN, human papillo-
mavirus (HPV) status, history of conization or hysterec-
tomy, detailed description of BT, recurrence of VAIN or 
invasive vaginal carcinoma, and vital status. 
HDR-BT was delivered using an iridium-192 (192Ir)
source from Elekta Microselectron (Elekta, Stockholm, 
Sweden). The intracavitary vaginal BT technique at our 
institution is based on the single-channel vaginal cylin-
der or multichannel applicators. All HDR-BT plans were 
generated, with a 3D treatment planning system (Oncen-
tra Brachy Nucletron Elekta, Veenedaal, The Netherlands) 
to calculate the dose on computed tomography (CT) and 
magnetic resonance (MR) images. Doses were prescribed 
in high-risk clinical target volume (HR-CTV) defined as 
vaginal wall (5 mm depth), with cervical surface if existing. 
Patients were followed-up for six weeks after treat-
ment, then every three months for the first two years, 
and twice per year thereafter. Vaginal smears were taken 
every six months, and vaginoscopies and biopsies were 
obtained whenever required to confirm a recurrence. 
Late complications of the vagina were graded during 
follow-up examination using the Common Terminology 
Criteria for Adverse Events v.4.0 (CTCAE 4.0) [10]. We 
specifically considered vaginal stenosis, telangiectasia, 
and vaginal bleeding defined as follows: 
• Vaginal stenosis: mild vaginal shortening or narrow-
ing: asymptomatic (G1); not interfering with physical 
examination (G2) or interfering with the use of tam-
pons, sexual activity, or physical examination (G3); 
• Telangiectasia (TA): TA covering < 10% (G1) or > 10% 
(G2) of the vaginal mucosa; 
• Vaginal bleeding: minimal bleeding identified on 
clinical examination and with no indication to inter-
vention (G1); moderate bleeding, in which medical 
intervention was indicated (G2); severe bleeding, for 
which transfusion was indicated (G3). 
Recurrent dysplasia or progression to invasive cancer 
was recorded from the last day of BT. 
For the dose-report analysis, the International Com-
mission on Radiation Units & Measurements (ICRU) of 
bladder and rectal points [11] were used as surrogate 
points of the anterior and posterior vaginal wall, respec-
tively. Both points were defined according to the patient 
coordinate system on anterior-posterior lines, which 
were strictly perpendicular to the patient’s longitudinal 
axis. However, we did not use a classical tandem and 
ovoid or tandem and ring for treatment, the rectal point 
was positioned from the top of the vaginal cylinder on 
a straight anterior-posterior line and on the intersection 
on the axis perpendicular to the body axis, 5 mm dorsal 
to the posterior vaginal wall. 
The vaginal applicators used meant that the poste-
rior-inferior order of the symphysis (PIBS) vaginal dose 
points were not useful to study the dose along the vaginal 
axis [12]. PIBS points were used to derive reference points 
as surrogates for the dose distribution at the mid-vagina, 
the transition from mid to lower, and at the lower vagina 
as follows: 
• Point 1 (P1): from the PIBS (defined as 2 cm posterior 
to the posterior-inferior border of the pubic symphy-
sis) on a straight anterior-posterior line perpendicular 
to the patient axis at the point where this line crosses 
the urethra; 
• Point 2 (P2): from P1, 2 cm up along the vaginal axis 
(at the level of PIBS+2); 
• Point 3 (P3): from P1, 2 cm down along the vaginal 
axis (at the level of PIBS-2) (Figure 1). 
P1, P2, and P3 were at a median distance of 0.5 cm 
(range, 0.4-0.6) from the vaginal applicators. 
For each fraction, we retrospectively collected the 
dose received by these points. Total doses were recalculat-
ed to the biologically equivalent doses and fractionation 
given with 2 Gy per fraction (EQD2) using the equation: 
EQD2 = nd (d + α/β)/(2 Gy + α/β), where n is the num-
ber of fractions and d the dose (Gy) per fraction (assum-
ing α/β = 10 Gy for tumor control, and α/β = 3 Gy for late 
normal tissue damage). For vaginal tissue, we assumed 
α/β = 3 because of the non-invasive nature of VAIN. 
Endpoints and statistical analysis 
The aim of this paper was to report a single-institu-
tion study of the application of high-dose-rate BT and to 
evaluate clinical outcomes as well as to investigate the 
dose-effect relationship for vaginal stenosis. 
For the present analyses, we used information record-
ed in the dataset about age, total and fractional doses in 
Gy and EQD2 units, doses received by each point (P1, P2, 
P3, rectal and bladder, as specified above), type and corre-
sponding grade of toxicity, previous treatment for VAIN 
(yes/no), and previous hysterectomy (yes/no). First, we 
did a descriptive statistical analysis, and data were pre-
sented with a boxplot, radar plot (continuous variables), 
or bar chart (discrete variables). Second, we used distri-
bution-free tests (appropriate for small data sets and lack 
of knowledge of the underlying distribution), with an ex-
plorative aim, since they suffer low power. We used the 
Fig. 1. Vaginal points 
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Kruskal Wallis test and Fisher’s exact tests to investigate 
the relations between continuous and categorical vari-
ables and vaginal stenosis (G < 2 or G ≥ 2), respectively. 
All statistical analyses were completed with the SAS 
(Version 9.4; SAS Institute, Inc., Cary, NC), adopting 
a significance level of α = 0.05.
Results 
Patients 
At diagnosis, all patients were asymptomatic, with 
HPV infection. Their ages ranged between 43 and 77 
years (median, 60.5 years) and the median follow-up was 
32.7 months (range, 10.5-89.83 months). Six patients had 
undergone hysterectomy for cervical cancer, three for cer-
vical dysplasia, and one for benign disease. Two women 
had had previous treatment for VAIN grade 3, one with 
5-fluorouracil (5-FU) 5% cream for vaginal self-applica-
tion, and the other with laser ablation of the Lugol-iden-
tified vaginal lesion. 
Treatments 
All patients had plans for each fraction, and treatment 
was delivered twice a week for a mean of 15 days (range, 
8-20 days). The total radiation dose range was 24-42 Gy, 
with a median of 35 Gy; the total recalculated EQD2 range 
was 43.2-75.6 Gy (median, 56 Gy). Fraction sizes are re-
ported in Table 1. Of the 14 registered patients, 13 had 
complete dosimetric data and were considered in the do-
simetric analysis. Table 2 summarizes the doses received 
to P1, P2, P3, rectal, and bladder points. 
After HDR-BT all patients used topical therapy with 
hyaluronic acid or/and vitamin E vaginal suppositories. 
Complications of brachytherapy 
Treatment was well tolerated, and no interruption was 
necessary. Acute toxicity was minimal, and most com-
plaints were grade 1 urinary complications (5 patients). 
However, all patients had some late vaginal symptoms. 
During the follow-up, 5 patients developed vaginal ste-
nosis G2 and 3 women had G3 (Figure 2). Since vaginal 
stenosis seemed to be the most frequent complaint, we 
focused our analysis by dichotomizing it on the basis of 
less than G2 or G2 and more. 
Previous treatments for VAIN, previous hysterecto-
my, overall BT treatment time, total dose, and dose per 
fraction seemed not to be related to vaginal stenosis G ≥ 2. 
Total doses delivered to each point are presented and ac-
cording to the grade of stenosis in Figure 3B. Per point dose 
and demographic analysis gave interesting (Figure 3A) 
results about the toxicity relationship with rectal point 
dose and age, respectively. Women with G ≥ 2 stenosis 
received a higher median dose (Figures 3C and 4) and, 
in line with the published age cutoff, were > 60 years 
old (Figure 5). No statistical significance was observed 
for these findings (Kruskal Wallis test: p = 0.391, Fish-
er’s exact test: p = 0.286 for rectal dose and age analysis, 
respectively). However, the underpowered non-para-
metric test means it is hard to establish whether the real 
Table 1. Treatment characteristics 
Characteristics Number of patients 
Fraction size 
5 Gy × 7 fractions 7 
5 Gy × 6 fractions 1 
5.6 × 7 fractions 1 
5.9 × 7 fractions 1 
6 Gy × 4 fractions 1 
6 Gy × 7 fractions 3 
Table 2. Descriptive statistics of dose (cGy) received to P1, P2, P3, rectal, and bladder points of the 13 analyza-
ble patients 
Dose points Minimum (cGy) 25th centile (cGy) Median (cGy) 75th centile (cGy) Maximum (cGy) IQR (cGy) 
p1 1114.38 2702.44 3009.67 3163.01 4161.16 460.57 
p2 2446.24 3042.46 3549.41 3742.42 4578.09 699.96 
p3 404.05 1270.82 1576.30 1906.13 2492.77 635.31 
Rectal 2034.19 2801.51 3251.94 3978.17 5029.87 1176.66 
Bladder 1494.67 1851.20 2097.58 2426.68 2910.65 575.48 
IQR – interquartile range, 75th centile-25th centile 
Fig. 2. Vaginal toxicity. Bar-chart showing the toxicity’s 
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differences are only too small to be detected or actually 
do not exist. 
Discussion 
Treatment for VAIN is based on grade and focality 
(uni- or multifocal), and the treatment modalities avail-
able are medical, surgical, and radio-therapeutic. For se-
lected healthy women, conservative management may be 
considered. Medical management, which can give cure 
rates of 45-100% is recommended for patients with per-
sistent HPV infection and multifocal VAIN. It consists 
of trichloroacetic acid, 5-fluorouracil, and an immune 
response modifier (5% imiquimod, cidofovir). Therapeu-
tic vaccine expressed HPV 16-18 oncoproteins E6 and E7, 
and poly-gamma-glutamic acid is still under investiga-
tion [13,14,15,16,17,18,19]. 
Surgical treatments involve CO2 laser ablation (suc-
cessful in 70.8-79.2%), surgical excision (successful in 
66-87%), cavitational ultrasonic surgical aspiration (CUSA), 
Fig. 3. Radar plots with radiation doses (cGy) depicted on 
different spokes, corresponding to P1, rectal, P2, bladder, 
and P3, in a clockwise direction. The distance between the 
point on the spoke and the center of the radar plot indicates 
the radiation dose in that PIBS-point. Lines connecting the 
points on different spokes give the dose pattern. A) Radar 
plot depicting the pattern of the radiation dose (cGy) for each 
patient. B) Radar plot depicting the pattern of the radiation 
dose (cGy) for patients with stenosis G ≥ 2 (red lines) and G < 2  
(blue lines). C) Radar plot reporting the pattern of the medi-
an dose (cGy) calculated on the total of the patients (dotted 




Fig. 4. Distribution of dose received to rectal point. Box 
plots reflecting the distribution of dose in patients with G 
< 2 and G ≥ 2. Each box indicates the 25th and 75th centiles. 
The horizontal line inside the box indicates the median, 
and the whiskers indicate the extreme measured values. 
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Fig. 5. Age and toxicity. Bar-chart showing the percentage 
of patients over (red) and under (blue) 60 years, in the two 
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with a cure rate of 74% [20,21,22]. BT is acknowledged as 
an effective option, with high cure rates. In all reports, 
this treatment was well tolerated, with no limiting toxici-
ties; the main late toxicity is vaginal, such as stenosis and 
ulcer (Table 3) [23,24,25,26,27,28,29]. 
After assessment by the multidisciplinary committee 
of gynecologic oncology, patients were selected for BT 
considering the multifocality of the disease. In our cohort, 
the HR-CTV is the whole length of the vagina because of 
the focality of VAIN. Since the vagina is also an organ 
at risk, we considered it worthwhile to assume α/β = 3 
both for VAIN (a non-invasive disease) and for the whole 
vaginal tissue. 
Vaginal BT may cause chronic vaginal alterations 
with direct damage to the vaginal mucosa, connective tis-
sues, and microvasculature, resulting in secondary muco-
sal atrophy and increased collagen production that leads 
to shortening and tightening of the vagina. Pathological 
dilation of capillaries results in telangiectasia, tending to 
bleeding. In addition, adhesions and fibrosis cause loss of 
elasticity and some women may develop complete oblit-
eration of vagina [30,31,32]. 
Radiation-induced vaginal morbidity occurring with-
in the first two years after the end of treatment is still 
a substantial problem, calling for further attention. 
Since vaginal stenosis is the most frequent late effect 
and tends to persist, we focused our toxicity analysis on 
this issue. The damage to the epithelium was exacerbated 
by menopausal status, resulting in a further decrease in 
lubrication and thinning of vaginal tissues. Patients with 
stenosis more than or equal to 2 accounted for 86% and 
29%, respectively, among the over-60s and those aged 
60 or less. 
A points-based reporting method is generally used 
for the dose evaluation of bladder and rectum, but no 
clear recommendations for dose-volume parameters of 
the vagina have been developed so far. In the Embrace 
study (image-guided intensity-modulated external beam 
radiochemotherapy and MRI-based adaptive brachyther-
apy in locally advanced cervical cancer), the ICRU rectal 
point is suggested as a surrogate point to predict vaginal 
morbidity. Kirchheiner et al. showed an increase in the 
risk of vaginal stenosis for increasing the EQD2 dose to 
the reference recto-vaginal point, and a planning aim of 
85 Gy EQD2 (sum of external beam radiotherapy and BT) 
was proposed in order to reduce morbidity [33]. 
In our study, women who received a higher median 
dose to the rectal point developed major vaginal stenosis, 
even though we did not find any statistically significant 
evidence. Since non-parametric tests can suffer low pow-
er mainly due to small sample size, there may be a true 
effect or just a smaller difference that the underpowered 
non-parametric test cannot detect. For this reason, our re-
sults need to be reassessed in future studies. 
Total dose and dose per fraction did not seem related 
to G ≥ 2 vaginal stenosis. It is worth noting that one wom-
an who received a total dose of 24 Gy in four fractions 
presented G3 toxicity after a follow-up of 37.53 months. 
Major limitations of this study are the small sample 
and the retrospective analysis. However, the findings 
might prove useful as a starting point, since the rarity of 
this malignancy and limited BT approach for VAIN would 
require substantial resources for prospective studies. 
Conclusions 
This study found that HDR-BT was an effective, fea-
sible, and well tolerated treatment for VAIN. In spite of 
high cure rates, we must still clarify issues regarding vag-
inal toxicity, the woman’s age, and the total dose deliv-
ered to the rectal point in order to reduce complications. 
Applicable dose limits to the vagina are needed to 
apply them when planning therapy to improve patients’ 
quality of life. Therefore, this field merits further investi-
gation to reach robust and significant results.
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